GENE ONLINE|News &
Opinion
Blog

2020-03-24| COVID-19Technology

QuarkBio Announces a COVID-19 Test Kit, 10 Times More Sensitive than Existing Kits

by GeneOnline
Share To

Quark Biosciences Inc. announced today the successful development of a novel digital PCR test, DigiChip SARS-CoV-2 Assay, that is 10x more sensitive than conventional diagnostic methods.

The DigiChip SARS-CoV-2 assay utilizes QuarkBio’s proprietary dqPCR platform and high-density gene chip, which can simultaneously perform absolute quantification (digital PCR – dPCR) and real-time quantitative analysis in the same reaction, thus increasing both sensitivity and accuracy. The technology platform can analyze 6 samples concurrently, obtaining clinical results in less than 90 minutes.

Quark Biosciences plans to work with Shin Kong Memorial Hospital and a California-based medical group to launch clinical trials and apply for regulatory approval. The assay is capable of detecting minute amounts of virus presence, allowing for identification of patients at the early stages of infection and reducing false-negative results, an important leverage when working to contain the spread of the virus.

Dr. Cheng-Wey Wei, Director of Technology Development for QuarkBio, indicated that the digital functionality of the assay can detect as low as 3 copies of the virus in a sample, which is 10x more sensitive than conventional qPCR tests available in the market. Working tirelessly overnight and on weekends, his team has demonstrated the assay’s high level of precision, specificity, and impressive 8 logs of dynamic range. Dr. Jiann-Horng Yeh, the Vice President of Shih Kong Memorial Hospital, said the absolute quantification of the assay addresses a critical unmet need, which is the capability of monitoring virus load in patients recovering from COVID-19. Tracking the amount of virus load in patients in real-time is essential for the care of the patients and the safety of medical professionals.

Another issue in the diagnosis of SARS-CoV-2 is difficulty in acquiring samples. Typically, a throat swab is performed to obtain patient samples, but the procedure is laborious and potentially causes misdiagnosis. Due to its ultra-sensitivity, DigiChip SARS-CoV-2 Assay can be employed to analyze blood samples with a low amount of virus count.

Learn more about the panel chip:

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
R&D
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
GeneOnline’s Weekly News Highlights: Sept 11-Sept 15
2023-09-19
LATEST
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
2024-07-18
EVENT
Scroll to Top